$38.49
▲ +2.8% Today
as of Jul 22, 09:06 ET
Last 30 days
Recent Press Releases & News
MapLight Therapeutics Seen Having Upside in Schizophrenia Trial Readout, UBS Says
UBS Adjusts MapLight Therapeutics Price Target to $52 From $48, Maintains Buy Rating
BMO Capital Initiates MapLight Therapeutics at Outperform With $46 Price Target
Overview
52-week range
$12
$33
100% of range
Avg surprise (last 1)
-47.2%
Avg reaction (last 1)
-4.5%
0% positive
Latest IV / EM
343%
EM ±79.7% · $35 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-1.34 | $-0.91 | -47.2% | — | -4.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-37.18 | — | — | — | — | financials |
| Mon Mar 31, 2025 | Mar 2025 | $-29.33 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-25.08 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$1.37 | — |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-65M | — | $-31M | — | $-24M | — | $-21M | — |
| Net income | $-61M | — | $-29M | $-30M | $-22M | — | $-19M | $-18M |
| EPS (diluted) | $-1.34 | — | $-37.18 | — | $-29.33 | — | $-25.08 | — |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $56M | $47M | $64M | — | — | $38M | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $327M | $325M | $245M | — | — | $115M | — | — |
| Total assets | $419M | $480M | $257M | — | — | $137M | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $19M | $21M | $24M | — | — | $22M | — | — |
| Total equity | $400M | $458M | $-274M | $-245M | $-216M | $-194M | $-172M | $-154M |